International journal of dermatology · 2025
Cutaneous Side Effects of PD-1 Inhibitors: A Single-Center Retrospective Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pozsgai Melánia, Sebastian Udoh Frieda-Rex, Oláh Péter, Németh Viktória, Gyulai Rolland, Lengyel Zsuzsanna
Аннотация
BACKGROUND: The introduction of immune checkpoint inhibitors (ICIs) opened a new era in cancer immunotherapy. In particular, PD-1 inhibitors have shown remarkable efficacy in various cancers, most notably melanoma. However, the widespread use of immune checkpoint inhibitors comes with the challenge of immune-related adverse events (irAEs), with cutaneous toxicities being the most prevalent.
METHODS: A retrospective, single-center study was carried out to investigate the cutaneous side effects in patients diagnosed with melanoma and treated with PD-1 inhibitors (pembrolizumab or nivolumab) at the Department of Dermatology, Venereology, and Oncodermatology, University of Pécs, Hungary. The study included patients with stage III or IV melanoma who received PD-1 inhibitor monotherapy, either for metastatic or adjuvant purposes, from August 2015 to May 2022.
RESULTS: A cohort of 174 patients was examined, with 29% experiencing cutaneous adverse events (cAEs). The most prevalent cutaneous toxicities were vitiligo (n = 18; 27%), maculopapular rash (n = 14; 21%), pruritus (n = 14; 21%), xerostomia (n = 8; 12%), and lichenoid dermatitis (n = 4; 6%). Treatment primarily involved topical corticosteroids and emollients, with a few cases requiring systemic therapy. Notably, the occurrence of dermatologic adverse events was associated with improved progression-free survival (PFS) (p = 0.007) and overall survival (OS) (p = 0.026) compared to those without any skin toxicity (p < 0.0001), emphasizing their potential prognostic significance. Our data were not influenced by any well-known prognostic factors of melanoma.
CONCLUSION: Our study contributes to the growing body of evidence supporting the prognostic value of cutaneous adverse events in patients treated with PD-1 inhibitors. Optimizing treatment strategies while maintaining oncologic therapy is essential, highlighting the role of dermatologists in multidisciplinary cancer care.
METHODS: A retrospective, single-center study was carried out to investigate the cutaneous side effects in patients diagnosed with melanoma and treated with PD-1 inhibitors (pembrolizumab or nivolumab) at the Department of Dermatology, Venereology, and Oncodermatology, University of Pécs, Hungary. The study included patients with stage III or IV melanoma who received PD-1 inhibitor monotherapy, either for metastatic or adjuvant purposes, from August 2015 to May 2022.
RESULTS: A cohort of 174 patients was examined, with 29% experiencing cutaneous adverse events (cAEs). The most prevalent cutaneous toxicities were vitiligo (n = 18; 27%), maculopapular rash (n = 14; 21%), pruritus (n = 14; 21%), xerostomia (n = 8; 12%), and lichenoid dermatitis (n = 4; 6%). Treatment primarily involved topical corticosteroids and emollients, with a few cases requiring systemic therapy. Notably, the occurrence of dermatologic adverse events was associated with improved progression-free survival (PFS) (p = 0.007) and overall survival (OS) (p = 0.026) compared to those without any skin toxicity (p < 0.0001), emphasizing their potential prognostic significance. Our data were not influenced by any well-known prognostic factors of melanoma.
CONCLUSION: Our study contributes to the growing body of evidence supporting the prognostic value of cutaneous adverse events in patients treated with PD-1 inhibitors. Optimizing treatment strategies while maintaining oncologic therapy is essential, highlighting the role of dermatologists in multidisciplinary cancer care.